These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27401793)

  • 1. A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.
    Bregman N; Thaler A; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N;
    Brain Struct Funct; 2017 Apr; 222(3):1207-1218. PubMed ID: 27401793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
    Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
    Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.
    Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Shenhar-Tsarfaty S; Mirelman A
    J Neurol; 2021 Apr; 268(4):1517-1525. PubMed ID: 33388928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.
    Artzi M; Even-Sapir E; Lerman Shacham H; Thaler A; Urterger AO; Bressman S; Marder K; Hendler T; Giladi N; Ben Bashat D; Mirelman A
    PLoS One; 2017; 12(4):e0175424. PubMed ID: 28406934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers.
    Jacob Y; Rosenberg-Katz K; Gurevich T; Helmich RC; Bloem BR; Orr-Urtreger A; Giladi N; Mirelman A; Hendler T; Thaler A
    Hum Brain Mapp; 2019 Jun; 40(8):2546-2555. PubMed ID: 30793410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intact working memory in non-manifesting LRRK2 carriers--an fMRI study.
    Thaler A; Helmich RC; Or-Borichev A; van Nuenen BF; Shapira-Lichter I; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T; Mirelman A;
    Eur J Neurosci; 2016 Jan; 43(1):106-12. PubMed ID: 26536050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation.
    Thaler A; Gonen T; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Bloem BR; Giladi N; Hendler T;
    Brain Imaging Behav; 2019 Aug; 13(4):1009-1020. PubMed ID: 29971685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
    Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord; 2022 Jan; 37(1):190-195. PubMed ID: 34550621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
    Thaler A; Mirelman A; Helmich RC; van Nuenen BF; Rosenberg-Katz K; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T;
    Cortex; 2013 Oct; 49(9):2501-11. PubMed ID: 23357204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers.
    Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Shirvan JC; Cedarbaum JM; Orr-Urtreger A; Regev K; Shenhar-Tsarfaty S; Mirelman A
    J Parkinsons Dis; 2021; 11(3):1285-1296. PubMed ID: 33998549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset.
    Gan-Or Z; Giladi N; Rozovski U; Shifrin C; Rosner S; Gurevich T; Bar-Shira A; Orr-Urtreger A
    Neurology; 2008 Jun; 70(24):2277-83. PubMed ID: 18434642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.
    Thaler A; Shenhar-Tsarfaty S; Shaked Y; Gurevich T; Omer N; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Giladi N; Mirelman A
    Sci Rep; 2020 Jun; 10(1):9329. PubMed ID: 32518334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease.
    Liu SY; Zheng Z; Gu ZQ; Wang CD; Tang BS; Xu YM; Ma JH; Zhou YT; Feng T; Chen SD; Chan P;
    Parkinsonism Relat Disord; 2018 Dec; 57():72-76. PubMed ID: 30119933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.
    Pont-Sunyer C; Iranzo A; Gaig C; Fernández-Arcos A; Vilas D; Valldeoriola F; Compta Y; Fernández-Santiago R; Fernández M; Bayés A; Calopa M; Casquero P; de Fàbregues O; Jaumà S; Puente V; Salamero M; José Martí M; Santamaría J; Tolosa E
    PLoS One; 2015; 10(7):e0132368. PubMed ID: 26177462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.
    Alcalay RN; Caccappolo E; Mejia-Santana H; Tang M-; Rosado L; Orbe Reilly M; Ruiz D; Ross B; Verbitsky M; Kisselev S; Louis E; Comella C; Colcher A; Jennings D; Nance M; Bressman S; Scott WK; Tanner C; Mickel S; Andrews H; Waters C; Fahn S; Cote L; Frucht S; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Payami H; Molho E; Factor S; Ottman R; Clark LN; Marder K
    Neurology; 2012 May; 78(18):1434-40. PubMed ID: 22442429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews.
    Dagan E; Schlesinger I; Kurolap A; Ayoub M; Nassar M; Peretz-Aharon J; Gershoni-Baruch R
    Dement Geriatr Cogn Disord; 2016; 42(1-2):1-6. PubMed ID: 27449028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
    da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
    J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.